Bring on tomorrow with TRELEGY, the #1 prescribed triple therapy for patients with COPD*
Context: *Based on IQVIA Patient Level Data as of May 2020.
Discover the TRELEGY difference
See the Data
TRELEGY has BROAD Coverage
% National Coverage
TRELEGY is covered* for % of commercial and % of Medicare Part D patients† nationally.
% Coverage in the area
TRELEGY is covered* for % of commercial and % of Medicare Part D patients† in
Individual access may vary by geography and plan benefit design.
*“Covered" is defined as any potential for reimbursement from a health plan and may include step edits, prior authorizations, and other restrictions. Formulary status may vary and is subject to change. Formulary coverage does not imply clinical efficacy or safety.
†“Patients" means covered lives for all commercial and employer payer types (excluding Managed Medicaid), and covered lives enrolled in Medicare payer types as calculated by MMIT as of March 2020.
Veterans Affairs (VA) and Indian Health Service (IHS) lives have been omitted when calculating the percentage of lives for this geography.
Source: Managed Markets Insight & Technology, LLC (MMIT), database as of March 2020.
What you need to know about this formulary information:
Individual access may vary by geography and plan benefit design.
Formulary status may vary and is subject to change. Formulary coverage does not imply clinical efficacy or safety. This is not a guarantee of partial or full coverage or payment. Consumers may be responsible for varying out-of-pocket costs based on an individual’s plan and its benefit design. Each plan administrator determines actual benefits and out-of-pocket costs per its plan’s policies.
Verify coverage with plan sponsor or Centers for Medicare & Medicaid Services. Medicare Part D patients may obtain coverage for products not otherwise covered via the medical necessity process.
One Inhaler. One Daily Inhalation. One Co-pay.*
Could simplified delivery of triple therapy make a big difference for your patients?
For patients with COPD, once-daily dosing with TRELEGY may help simplify delivery of triple therapy.
TRELEGY does not replace a rescue inhaler.
*One co-pay is not a guarantee of coverage or lower out-of-pocket costs for patients than alternative treatments. Formulary status and patient out‑of‑pocket costs may vary, may be up to the prescription’s retail cost, and are subject to change.
Designed to help patients with COPD breathe better today
TRELEGY delivers rapid and lasting improvements in lung function
As early as 15 minutes
TRELEGY provided improvement in FEV1 vs BREO, as measured by LS mean change from baseline in FEV1, beginning at 15 minutes on Day 11
TRELEGY is not a rescue inhaler and should not be used for the relief of acute symptoms.
Maintained for 24 hours
Improvement persisted for 24 hours on Day 1 and Day 841
In 2 replicate studies, the primary efficacy endpoint was trough FEV1 at Day 85. The LS mean change from baseline in trough FEV1 at Day 85 for TRELEGY (n=206 in each trial) vs placebo + BREO (n=206 in each trial) was 124 mL for trial 1 and 122 mL for trial 2.1
Trials 1 & 2: Study Description1,2
Design: Two 12-week, randomized, double-blind, parallel-group, multicenter studies were conducted to evaluate the efficacy and safety of INCRUSE or placebo added to BREO 100/25. Treatment with TRELEGY refers to patients who received INCRUSE added to BREO 100/25. Eligible patients entered a 4-week open-label run-in period following screening where they received BREO 100/25. Patients were then randomized to receive INCRUSE (n=206 in each trial) or placebo (n=206 in each trial) added to open-label BREO 100/25.
Patients: At screening, patients with COPD (mean age: 64 years) had a mean postbronchodilator percent predicted FEV1 of 46%, a mean postbronchodilator FEV1/FVC ratio: 0.48, and a mean mMRC score of 2.4.
